A new targeted treatment for early-stage breast cancer? – Harvard Health
Posted By admin on November 30, 2021
In the US, breast cancer is the most commonly diagnosed cancer in women, and the second leading cause of cancer-related deaths. Each year, an estimated 270,000 women and a far smaller number of men are diagnosed with it. When caught in early stages, its usually highly treatable.
A promising new form of targeted treatment may expand options available to some women with early-stage breast cancer linked to specific genetic glitches. (Early-stage cancers have not spread to distant organs or tissues in the body.)
You may have heard the term BRCA (BReast CAncer) genes, which refers to BRCA1 and BRCA2genes. Normally, BRCA genes help repair damage to our DNA (genetic code) that occurs regularly in cells throughout the human body.
Inherited BRCA mutations are abnormal changes in these genes that are passed on from a parent to a child. When a person has a BRCA mutation, their body cannot repair routine DNA damage to cells as easily. This accumulating damage to cells may help pave a path leading to cancer. Having a BRCA1 or BRCA2 mutation or both puts a person at higher risk for cancer of the breast, ovaries, prostate, or pancreas; or for melanoma. A persons risk for breast cancer can also be affected by other gene mutations and other factors.
Overall, just 3% to 5% of all women with breast cancer have mutations in BRCAgenes. However, BRCA mutations occur more often in certain groups of people, such as those with triple negative breast cancer (TNBC), Ashkenazi Jewish ancestry, a strong family history of breast and/or ovarian cancer, and younger women with breast cancer.
Certain types of breast cancer are commonly found in women with BRCA gene mutations.
Knowing what encourages different types of breast cancer to grow helps scientists develop new treatments, and helps doctors choose available treatments to slow or stop tumor growth. Often this involves a combination of treatments.
The OlympiA trial enrolled women with early-stage breast cancer and inherited BRCA1/BRCA2 mutations. All were at high risk for breast cancer recurrence despite standard treatments.
Study participants had received standard therapies for breast cancer:
They were randomly assigned to take pills twice a day containing olaparib or a placebo (sugar pills) for one year.
Olaparib belongs to a class of medicines called PARP inhibitors. PARP (poly adenosine diphosphate-ribose polymerase) is an enzyme that normally helps repair DNA damage. Blocking this enzyme in BRCA-mutated cancer cells causes the cells to die from increased DNA damage.
Results from this study were published in the New England Journal of Medicine. Women who received olaparib were less likely to have breast cancer recur or metastasize (spread to distant organs or tissues) than women taking placebo. Follow-up at an average of two and a half years showed that slightly more than 85% of women who had received olaparib were alive and did not have a cancer recurrence, or a new second cancer, compared with 77% of women treated with placebo.
Further, the researchers estimated that at three years:
The side effects of olaparib include low white cell count, low red cell count, and tiredness. The chances of developing these were low.
Olaparib is already approved by the FDA to treat BRCA-related cancers of the ovaries, pancreas, or prostate, and metastatic breast cancer. FDA approval for early-stage breast cancer that is BRCA-related is expected soon based on this study. These findings suggest taking olaparib for a year after completing standard treatment could be a good option for women who have early-stage breast cancer and an inherited BRCA gene mutation who are at high risk for cancer recurrence and, possibly, its spread.
Follow me on Twitter @NeelamDesai_MD
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
See more here:
A new targeted treatment for early-stage breast cancer? - Harvard Health
- A Cry in the Wilderness: How Jewish Organizations Can Help With Jewish Genetic Diseases - Jewish Journal - August 12th, 2022
- Azerbaijan's Minister of Youth and Sports meets with Chief Rabbi of Ashkenazi Jewish community in country - AZERTAC News - August 12th, 2022
- Czerny as the new Lustiger, the 'Jewish cardinal' and papal contender - Crux Now - August 12th, 2022
- Honoring the Jews of Jamaica | Jewish & Israel News Algemeiner.com - Algemeiner - August 12th, 2022
- Anne Frank, Arab-Jewish relations, karaoke in focus at upcoming Israeli film awards - The Times of Israel - August 12th, 2022
- Metas new chatbot is already parroting users prejudice and misinformation - Popular Science - August 12th, 2022
- Meet the Jews of color exploring what it means to be Black, Asian, Latino and Jewish - Forward - August 12th, 2022
- Jewish wilderness wedding featured animal-skin ketubah, harvest altar J. - The Jewish News of Northern California - August 12th, 2022
- Ashkenazi Jewish Panel: What It May Reveal About Your Genes - July 23rd, 2022
- At SFJFF opening night, we're all just happy to be back at the Castro J. - The Jewish News of Northern California - July 23rd, 2022
- Verimatrix and Harmonic Partner to Enable Streaming Content Protection at SaaS Speed - StreetInsider.com - July 23rd, 2022
- Russian cuisine has evolved in light of scarcity and isolation - KCRW - July 23rd, 2022
- Tina Sacks on racial inequality in health and feeling 'Jewish enough' - The Jewish News of Northern California - July 23rd, 2022
- Who serves the best kosher pizza in NYC? We found out - Forward - July 23rd, 2022
- Fight Over Fear: Ayesha Khan on the importance of mammograms in fighting breast cancer - FOX 5 DC - July 14th, 2022
- I was named after my uncle who was shot and killed. His Hebrew name is a privilege I dont bear lightly - Forward - July 14th, 2022
- Groups Launched to Help Jewish Couples with IVF Face Uncertain Landscape After Roe Reversal - Jewish Exponent - July 14th, 2022
- Tipping Point: Israel on the Brink The Brooklyn Rail - Brooklyn Rail - July 14th, 2022
- World Premiere of ASHKENAZI SEANCE to be Presented at The Brick This Month - Broadway World - July 10th, 2022
- Lentils Make the Best Fake Minced Meat - Lifehacker - July 10th, 2022
- Liberal Pakistani Writer And Nuclear Scientist Dr. Pervez Hoodbhoy: 'European Jews Fleeing Hitler Were Far Less Welcome Than Muslims Are In Today's... - July 10th, 2022
- Book Appreciation: AB Yehoshua's "Mr Mani" -- A Great Work of Fiction - artsfuse.org - July 10th, 2022
- The secret Plymouth graveyard unearthed behind this door with the aid of Google and a box of old keys - Plymouth Live - July 10th, 2022
- Bustle's Guide To Abortion Care - Bustle - June 26th, 2022
- Op-Ed: A notebook with family recipes reminds me of Ukraines strength - Los Angeles Times - June 26th, 2022
- Hey Pandas, Who Has An Unusual Ethnic Background That Has Everyone Wondering What You're Mixed With? - Bored Panda - June 26th, 2022
- Pompe Diseases Enzyme Replacement Therapy (ERT) Market is predicted to increase at a high 7% CAGR ov - PharmiWeb.com - June 26th, 2022
- A Rare Tanach And The Ladino Renaissance - The Jewish Press - JewishPress.com - June 17th, 2022
- I Never Met My Jewish Father. Converting to Judaism Helped Me Forgive Him. Kveller - Kveller.com - June 17th, 2022
- Failing to Silence the Jewish Fiddle - Jewish Journal - June 17th, 2022
- The ADL, Progressives and White Nationalists - City Watch - June 17th, 2022
- Verimatrix Threat Defense Technology Wins 2022 Global Infosec Award - TechDecisions - June 17th, 2022
- Obituary Bernard Allan Lublin - The Henrico Citizen - Henrico Citizen - June 17th, 2022
- Mayo Clinic Q and A: What is the benefit of visiting a genetic counselor? - Times-West Virginian - June 17th, 2022
- A lesbian Orthodox horror movie and other Jewish highlights of the 2022 Tribeca Film Festival - JTA News - Jewish Telegraphic Agency - June 8th, 2022
- Have You Ever Heard of the Farhud? - Jewish Journal - June 8th, 2022
- Eating Your Way Through The Beauty Queen of Jerusalem - aish.com - Aish - June 8th, 2022
- Why cold summer soups are actually really Jewish - St. Louis Jewish Light - June 8th, 2022
- Ben M. Freeman Wants Jews To Be Proud of Their Heritage - jewishboston.com - June 8th, 2022
- Our daughter had a year left to live. We had to do something wonderful with the time she had left. - The Boston Globe - June 8th, 2022
- An MRI detected breast cancer in this Haddonfield woman. Should you consider having one? - The Philadelphia Inquirer - June 8th, 2022
- Ashkenazi versus Sephardic Jews - aish.com - June 4th, 2022
- Here are the films that are welcoming back NYCs Israel Film Center Festival - The Times of Israel - June 4th, 2022
- Mom worries about husband's family history of breast cancer - The Independent - June 4th, 2022
- Biblio File: The Treasure of the Jews - Australia/Israel & Jewish Affairs Council - June 4th, 2022
- Bat Shlomo Winery one-of-a-kind - Cleveland Jewish News - June 4th, 2022
- Are These The Best Lyrics From the 2022 Tony Nominees for Best Original Score? - Playbill.com - June 2nd, 2022
- The Joy of Sour Cream - Tablet Magazine - June 2nd, 2022
- Meet? Meh. Zoom? Zzz. Here's the future of online meetings - Fast Company - May 27th, 2022
- 8 tips to help journalists cover antisemitism and avoid spreading it - Journalist's Resource - May 27th, 2022
- When is Shavuot 2022? Date of Jewish holiday | NationalWorld - NationalWorld - May 27th, 2022
- Is is colon cancer hereditary or genetic? - Medical News Today - May 27th, 2022
- Advanced amphibious landing capabilities improve Israel's ability to win - JNS.org - May 27th, 2022
- Boom, there was a community: Washingtons Jewish future guided by history - MyNorthwest - May 27th, 2022
- Only countries that continue to innovate can lead - CTech - May 27th, 2022
- Rescuing Ladino from the Flames of History - aish.com - Aish - May 2nd, 2022
- By the numbers, corporate progress on gender diversity is a failure - CNBC - May 2nd, 2022
- On National Rugelach Day, A Look Into the History of Rugelach in NYC - Untapped New York - May 2nd, 2022
- As Montreal as? The mystery of the cheese bagel - Montreal Gazette - May 2nd, 2022
- World steps up fight against polio as new cases surface in Pakistan and Israel - The National - May 2nd, 2022
- How Richmond Restaurant JewFro Is Working to Bring Together Two Local Histories - Bon Appetit - May 2nd, 2022
- 'I live in peace with my two identities, Jewish and Arab - Haaretz - May 2nd, 2022
- Exhibit of Photographs and Family Artifacts Tells Little Known Story of Jewish Community in Shanghai - Broadway World - April 25th, 2022
- Local Authors, Local Books: Irvington Writer Unlocks the Mystery of Her Family - River Journal Staff - April 25th, 2022
- Students Partner with Holocaust Museum in Documenting Oral Histories of Latinx Sephardic Jewish Communities - University of Houston - April 25th, 2022
- Ashes On The Kotel: Analysis Of A Tense Situation - VINnews - April 25th, 2022
- Activist gets candid about pollution fears: 'Climate anxiety is real, especially for a young Indigenous woman' - Yahoo Singapore News - April 25th, 2022
- Get rid of that extra matzah with this Spinach Feta Matzah Brei J. - The Jewish News of Northern California - April 25th, 2022
- Fallopian Tube Cancer: Causes, Symptoms, Prevention and treatment - Rising Kashmir - April 25th, 2022
- Why this classic Romanian-Jewish dish is nearly impossible to find - Salon - March 22nd, 2022
- PART III: Confronting the elephant in the room the explosive issue of IQ - Genetic Literacy Project - March 22nd, 2022
- How the Academy Museums Jewish Exclusion Became Exhibit A - Hollywood Reporter - March 22nd, 2022
- Are virtual minyans and avatar rabbis the future of Judaism? - Forward - March 22nd, 2022
- Pancreatic Cancer Signs Scaring Doctors Most Eat This Not That - Eat This, Not That - March 22nd, 2022
- A Brief History of the Jewdle - Tablet Magazine - March 18th, 2022
- CORRECTING and REPLACING: Verimatrix Selected to Safeguard Alphazet's Streaming Service - Business Wire - March 18th, 2022
- Mila Kunis Net Worth, Salary, Investments and More - TheTealMango - March 18th, 2022
- A rabbi, a clown and a sushi chef walk into a restaurant. They're here to celebrate Purim - The Arizona Republic - March 18th, 2022
- Bill Ackmans Net Worth, Financial Situation, and Investments - The Shahab - March 10th, 2022
- Resituating US History in a Global Context | Higher Ed Gamma - Inside Higher Ed - March 10th, 2022
Comments